Zydus Lifesciences Receives FDA Warning Letter Over Component Testing Failures at Baddi Facility

Incoming material qualification programs at facilities supplying the U.S. market are under renewed scrutiny after Zydus Lifesciences Limited received an FDA warning letter dated June 2, 2026, citing significant violations of 21 CFR Parts 210 and 211 at its Baddi, Himachal Pradesh site (FEI 3005430968). The agency reviewed records submitted under a section 704(a)(4) request issued in November 2025 and concluded that the facility's manufacturing controls do not conform to current GMP, rendering affected drug products adulterated under section 501(a)(2)(B) of the FD&C Act.

The central violation involves a failure to adequately test incoming drug components before release into manufacturing, as required under 21 CFR 211.84. FDA's review focused on a prescription drug product containing a component classified as higher-risk due to a known human carcinogen that can be present as a contaminant. Scientific literature dating to the 1960s has associated this contaminant with elevated incidence of certain conditions when the product is applied to specific body areas. Zydus's product labeling permits use in those same areas, compounding the patient safety concern.

The specific analytical gap identified by FDA is technically precise: while Zydus's internal specifications reference current USP absence-of-contaminant procedures using Infrared (IR) Spectroscopy, the instrument reports on file covered a wavenumber range that excluded the critical spectral windows required by the current USP method. No scale expansions at the required wavenumbers were documented. Critically, FDA's review of available spectral data identified absorption features in the regions corresponding to those critical wavenumbers across multiple lots, raising the possibility that the contaminant was present and undetected.

For QA directors and incoming materials teams, the compliance read is direct: IR-based identification testing must be validated against the current compendial method in its entirety, including all required wavenumber ranges and scale expansion steps. Instrument configuration and data capture settings should be audited against the version of the USP monograph in effect at the time of testing. Where a component carries a carcinogen contamination risk and the finished product has a defined patient exposure profile, the risk-based justification for any abbreviated testing approach will face heightened agency scrutiny.

The warning letter was issued by the Center for Drug Evaluation and Research (CDER) and addressed to Managing Director Dr. Sharvil Patel. No import alert status was referenced in the publicly available text, but facilities in receipt of warning letters under 704(a)(4) review typically face continued records scrutiny pending a satisfactory CAPA response.

Resolution will hinge on Zydus demonstrating, through updated analytical procedures and retrospective lot disposition assessments, that its component testing program now fully conforms to current USP specifications across all higher-risk materials.

Source: FDA CDER via What's New: Drugs RSS Feed, June 9, 2026. Warning Letter reference 320-26-92, dated June 2, 2026.